Frequency of somatic TP53 mutations in non-small cell lung cancer in Kazakhstan

被引：0
|
作者：
Zhuraliyeva, A. [1 ]
Wang, J. [2 ]
Khamdiyeva, O. [1 ]
Abdullaev, Z. [2 ]
Pack, S. [2 ]
Biyasheva, Z. [1 ]
机构：
[1] Al Farabi Kazakh Natl Univ, Sci Res Inst Issues Biol & Biotechnol, Alma Ata, Kazakhstan
[2] NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA
来源：
FEBS OPEN BIO | 2019年 / 9卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P-35-114
引用
收藏
页码：354 / 354
页数：1
相关论文
共 50 条
  • [31] Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer
    Mathiot, Laurent
    Nigen, Benoit
    Goronflot, Thomas
    Hiret, Sandrine
    Doucet, Ludovic
    Pons-Tostivint, Elvire
    Bennouna, Jaafar
    Denis, Marc G.
    Herbreteau, Guillaume
    Raimbourg, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis
    deAnta, JM
    Jassem, E
    Rosell, R
    MartinezRoca, M
    Jassem, J
    MartinezLopez, E
    Monzo, M
    SanchezHernandez, JJ
    Moreno, I
    SanchezCespedes, M
    ONCOGENE, 1997, 15 (24) : 2951 - 2958
  • [33] TP53 mutations reprogram fatty acid metabolism and tumor microenvironment in African American patients with non-small cell lung cancer
    Liu, Liang
    Mehraein-Ghomi, Farideh
    Forbes, Elizabeth
    Topaloglu, Umit
    Petty, W. Jeffrey
    Grant, Stefan
    Ruiz, Jimmy
    Foley, Kristie L.
    Winkfield, Karen
    Pasche, Boris
    Zhang, Wei
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [34] TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis
    Josep Maria de Anta
    Ewa Jassem
    Rafael Rosell
    Marta Martínez-Roca
    Jacek Jassem
    Eva Martínez-López
    Mariano Monzó
    José Javier Sánchez-Hernández
    Isabel Moreno
    Montserrat Sánchez-Céspedes
    Oncogene, 1997, 15 : 2951 - 2958
  • [35] TP53 mutations as predictor of response and longer survival under immune checkpoint inhibitors in advanced non-small cell lung cancer
    Assoun, S.
    Theou-Anton, N.
    Nguenang, M.
    Cazes, A.
    Danel, C.
    Abbar, B.
    Pluvy, J.
    Gounant, V.
    Khalil, A.
    Namour, C.
    Brosseau, S.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
    Erdem, Johanna Samulin
    Skaug, Vidar
    Bakke, Per
    Gulsvik, Amund
    Haugen, Aage
    Zienolddiny, Shanbeh
    BMC CANCER, 2016, 16
  • [37] Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
    Johanna Samulin Erdem
    Vidar Skaug
    Per Bakke
    Amund Gulsvik
    Aage Haugen
    Shanbeh Zienolddiny
    BMC Cancer, 16
  • [38] Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
    Li, Ming
    Zhang, Xiao-Lei
    Deng, Fang
    Qian, Li-Ting
    Meng, Shui-Ping
    Shan, Wu-Lin
    Wang, Bao-Long
    ONCOLOGY LETTERS, 2016, 12 (05) : 3330 - 3336
  • [39] Non-invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non-small cell lung cancer
    Wu, Zhen
    Yang, Zhen
    Li, Chun-Sun
    Zhao, Wei
    Liang, Zhi-Xin
    Dai, Yu
    Zeng, Jing
    Zhu, Qiang
    Miao, Kai-Ling
    Cui, Dong-Hua
    Chen, Liang-An
    ONCOLOGY LETTERS, 2019, 18 (04) : 3581 - 3590
  • [40] Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)
    Feng, J.
    Hueniken, K.
    Fan, Z. J.
    Corke, L.
    Leighl, N. B.
    Liu, G.
    Bradbury, P. A.
    Sacher, A.
    Eng, L.
    Stockley, T.
    Tsao, M. S.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S343 - S344
12345